GlassScriptPhysician profile
Margarita Lamothe
NPI 1306887187
$11,548.14
in general payments reported to CMS, 2019-2025
27 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 80% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,008 · 2020: $1,462 · 2021: $1,860 · 2022: $2,259 · 2023: $1,605 · 2024: $1,257 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,959.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,214.43 | 2019-2025 | |
| Viiv Healthcare Company | $1,687.15 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $1,248.65 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $1,101.79 | 2019-2025 | |
| Insmed, INC. | $1,013.64 | 2019-2025 | Arikayce, Brinsupri |
| La Jolla Pharmaceutical Company | $816.23 | 2020-2025 | Xacduro, Xerava, Zevtera |
| Cumberland Pharmaceuticals, INC. | $560.15 | 2019-2022 | |
| Pfizer INC. | $433.85 | 2019-2025 | |
| Theratechnologies INC. | $370.52 | 2019-2023 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $335.27 | 2019-2023 | Symtuza |
| Tetraphase Pharmaceuticals, INC. | $329.63 | 2019-2020 | |
| Allergan, INC. | $239.66 | 2019-2020 | |
| Melinta Therapeutics, LLC | $237.03 | 2019-2025 | Rezzayo, Vabomere, Kimyrsa |
| Astellas Pharma US INC | $220.27 | 2019-2023 | Cresemba |
| Biotissue Holdings INC. | $146.96 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $115.31 | 2021-2024 | Fetroja |
| Ferring Pharmaceuticals INC. | $105.87 | 2022-2023 | Rebyota |
| Mayne Pharma Commercial LLC | $74.01 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $66.01 | 2019-2024 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $54.46 | 2022 | |
| Emd Serono, INC. | $53.54 | 2019-2020 | |
| Triad Life Sciences INC. | $36.83 | 2022 | |
| Convatec INC. | $24.77 | 2023 | |
| Dynavax Technologies Corporation | $20.30 | 2023 | Heplisav-B |
| Nabriva Therapeutics, Plc | $16.21 | 2020 | |
| Medela LLC | $13.20 | 2020 | |
| Mylan Institutional INC. | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margarita Lamothe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.